TITLE

Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene

AUTHOR(S)
Mikkola, Hanna K. A.; Klintman, Jenny; Yang, Haidi; Hock, Hanno; Schlaeger, Thorsten M.; Fujiwara, Yuko; Orkin, Stuart H.
PUB. DATE
January 2003
SOURCE
Nature;1/30/2003, Vol. 421 Issue 6922, p547
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The production of blood cells is sustained throughout the lifetime of an individual by haematopoietic stem cells (HSCs). Specification of HSCs from mesoderm during embryonic development requires the stem cell leukaemia SCL/tal-1 gene product. Forced expression of SCL/tal-1 strongly induces blood formation in embryos, indicating that this gene has a dominant role in commitment to haematopoiesis. In the adult haematopoietic system, expression of SCL/tal-1 is enriched in HSCs and multipotent progenitors, and in erythroid and megakaryocytic lineages, consistent with roles for this factor in adult haematopoiesis. Here we assess by conditional gene targeting whether SCL/tal-1 is required continuously for the identity and function of HSCs. We find that SCL/tal-1 is dispensable for HSC engraftment, self-renewal and differentiation into myeloid and lymphoid lineages; however, the proper differentiation of erythroid and megakaryocytic precursors is dependent on SCL/tal-1. Thus, SCL/tal-1 is essential for the genesis of HSCs, but its continued expression is not essential for HSC functions. These findings contrast with lineage choice mechanisms, in which the identity of haematopoietic lineages requires continuous transcription factor expression.
ACCESSION #
9003626

 

Related Articles

  • AC133 expression in human stem cells. Bhatia, M // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1685 

    Expression of cell surface markers on human hematopoietic cells has provided a method for characterizing subsets of cells with distinct biological functions. This is largely due to the ability to separate highly purified subpopulations of cells for comparative analysis. Relationships between the...

  • Targeting Leukemia Stem Cells. Hampton, Tracy // JAMA: Journal of the American Medical Association;6/5/2013, Vol. 309 Issue 21, p2205 

    The article reports the identification on a new compound called RK-20449 by researchers of Japan and the U.S. that is found to inhibit hematopoietic cell kinase, a molecule critical to leukemia stem cells.

  • Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Heinzinger, M; Waller, C F; Rosenstiel, A; Scheid, S; Burger, K J; Lange, W // Leukemia (08876924);Mar98, Vol. 12 Issue 3, p333 

    Coexistence of Philadelphia chromosome (Ph)-negative, primitive hematopoietic progenitor cells with their malignant counterparts in chronic myelogenous leukemia (CML) has been reported. As most of the Ph-negative progenitor cells do not express the HLA-DR antigen, selection of them might be...

  • Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia. Guyotat, D; Wahbi, K; Viallet, A; Piselli, S; Campos, L // Leukemia (08876924);Jul99, Vol. 13 Issue 7, p991 

    Philadelphia (Ph) or BCR/ABL-negative cells with immature phenotype (CD34-positive, DR-negative) can be recovered from patients with chronic myeloid leukemia (CML) in chronic phase. We used the technique described by Berardi et al (Science 1995; 267: 104-108) to select stem cells from marrow or...

  • Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Anasetti, C // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p502 

    The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis....

  • Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation. Chen, Y-S; Kong, X-J; Zhang, X-H; Yin, X-L // Bone Marrow Transplantation;Jul2014, Vol. 49 Issue 7, p984 

    A letter to the editor is presented regarding the use of autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell microtransplantation to a 59-year-old man suffering from acute mixed-cell leukemia (AMAL).

  • Telomeres and telomerase in hematologic neoplasia. Ohyashiki, Junko H; Sashida, Goro; Tauchi, Tetsuzo; Ohyashiki, Kazuma // Oncogene;1/21/2002 Review, Vol. 21 Issue 4, p680 

    Normal hematopoietic cells express telomerase activity, however the presence of telomerase does not necessarily imply stable and thus unchanging telomere length. Gradual telomere loss with aging and rapid cycling of hematopoietic stem cells might contribute to immunosenescence, exhausted...

  • 13. Minitransplants.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS145 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S145–S154. DOI: 10.1038/sj/bmt/1703478

  • Molecular Long-Term Follow Up in Non-Human Primates That Received Retrovirally Transduced Stem Cells: Despite Proto-Oncogene Insertion No Leukemia or Hematopoietic Abnormalities  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p1 

    An abstract of the article "Molecular Long-Term Follow Up in Non-Human Primates That Received Retrovirally Transduced Stem Cells: Despite Proto-Oncogene Insertion No Leukemia or Hematopoietic Abnormalities," by Brian C. Beard and colleagues is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics